Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Trophos starts phase II clinical trial of TRO19622 in liver disease


Marseille, May 15th, 2008 - Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the first patients with NonAlcoholic SteatoHepatitis (NASH) have been enrolled in an exploratory Phase IIa clinical trial of its lead product, TRO19622. It is the first study investigating the potential benefits of TRO19622 beyond neurological conditions.

The randomized, double-blind, placebo-controlled, single dose trial will compare the efficacy of TRO19622 to placebo after 4 weeks of treatment in 30 patients with NASH. The exploratory study will assess the safety, tolerability and short term effect of 500mg TRO19622, once-a-day, on circulating liver enzymes and biomarkers of oxidative stress and apoptosis. The study is being conducted at centers in France and is expected to be completed in Q4 2008.

TRO19622 is representative of novel compounds identified using the proprietary neuronal cell screening platform developed at Trophos. Preclinical studies have demonstrated that these compounds promote the function and survival of neurons, cardiomyocytes and hepatocytes under various disease-relevant stress conditions, via a mitochondria-based mechanism of action. TRO19622 has successfully completed Phase I/Ib studies in both healthy volunteers and ALS patients, demonstrating the product is well tolerated, has an excellent safety profile and that once-a-day dosing achieves the predicted exposure level required for efficacy, based on preclinical models.

'The opportunity to perform this exploratory Phase IIa study with TRO19622 in patients with liver disease is a very significant event for the company, as it will provide evidence that the mechanism of action of this class of compounds will have therapeutic and commercial potential beyond neurological conditions,' said Antoine Béret, CEO of Trophos. 'Their mechanism of action and a battery of preclinical studies support the clinical evaluation of compounds in this class as treatments for liver disease, chronic neurological disorders and conditions involving ischemia-reperfusion injury, all indications with significant unmet medical needs and tremendous commercial potential.'

About NonAlcoholic SteatoHepatitis (NASH):
NonAlcoholic SteatoHepatitis is a 'silent' liver disease characterized by fatty infiltration of the liver together with signs of inflammation and hepatocyte injury. NASH affects 2 to 5 per cent of Americans and the worldwide increase in obesity and diabetes has resulted in NASH rapidly becoming recognized as one of the major and most prevalent causes of liver disease, ranking in the top three hepatopathies in different countries and ethnic backgrounds. While diet and lifestyle changes are always recommended, lack of compliance can result in NASH patients failing to achieve these objectives. NASH can lead to cirrhosis (est. 20% of cases) and ultimately to permanent liver damage & failure (est. 2-3% of cases), with organ transplantation the only treatment option. Hepatoprotection in patients with NASH is a significant unmet medical need and there is no approved treatment that decreases hepatic cytolysis or prevents fibrosis. For additional information on NASH see www.digestive.niddk.nih.gov/ddiseases/pubs/nash/

About Trophos: www.trophos.com
Trophos is a biopharmaceutical company committed to the discovery and development of novel therapeutic compounds to treat neurological disorders and other diseases with high unmet medical needs. The Trophos discovery strategy has enabled it to develop a portfolio of proprietary products, such as its lead product TRO19622 and drug candidate TRO40303, that confer a survival benefit to stressed neuronal and non-neuronal cells. This is achieved through a mitochondria-based mechanism of action with a robust scientific rationale predicted to exhibit therapeutic benefits in diseases such as neuropathic pain, ischemia-reperfusion injury and hepatotoxicity. T


Publisher Contact Information:

Andrew Lloyd & Associates
+44 1273 675100
neil@ala.com

Company profile of Trophos SA
Past press releases of Trophos SA.

Data


26,008
Tech investments
From our Online Data Service
16,823
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 19€7.0MAgriculture related
Aug 19€9.0MInternet commerce
Aug 19€10.0ME-Commerce
Aug 19€63.0MBusiness applications
Aug 16€16.0ME-Commerce
Aug 16€6.0MBusiness applications
Aug 15€20.0MGames

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.